Dr. Jeanette Boudreau is an associate professor at Dalhousie University, where she is developing novel, affordable and off-the-shelf therapies for cancer. Dr. Boudreau is driven to find new, less-toxic, more effective treatments for cancer that can be deployed within the Canadian public health-care system. Her laboratory merges genetic information with immunology, advanced model systems, AI and machine learning to understand the opportunities to improve immunotherapy for cancer.
Dr. Boudreau was a 2019 Terry Fox New Investigator with the Pan-Canadian immunoTherapeutics NeTwork (iTNT) and is now a co-principal investigator on the Terry Fox New Frontiers Program Project Grant for integrated immunotherapies for ovarian cancer. Dr. Boudreau’s work extends to the Marathon of Hope Cancer Centres Network, where she is leading genetics and immunologic assessments of Gold Cohort samples in the Atlantic Cancer Consortium, and leads a TFRI–MOHCCN Technology Development project that is developing reproducible, shareable systems for immunologic assessments of solid tumours.
Dr. Boudreau is the scientific director of the Beatrice Hunter Cancer Research Institute (BHCRI), an Atlantic Canada-wide consortium of cancer researchers, health-care providers, trainees and people with lived and living experience with cancer. BHCRI strives to foster the best cancer research by knitting together expertise across research pillars, striving toward a future with better cancer prevention, treatment, survivorship and cures.